Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: Who's afraid of the big bad wolf?

Leukemia Research

Volumn 36, Issue 7, 2012, Pages 813-814

  Breccia, Massimo ^a   Efficace, Fabio ^b   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Data Center and Health Outcomes Research Unit   (Italy)

Author keywords

CML; Dasatinib; Nilotinib; PAH; PAOD

Indexed keywords

CHOLESTEROL; DASATINIB; DISCOIDIN; GLUCOSE; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

AGE; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; CIGARETTE SMOKING; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPEREOSINOPHILIC SYNDROME; HYPERGLYCEMIA; HYPERTENSION; MEDICAL DECISION MAKING; NEUROPATHY; OBESITY; PATIENT MONITORING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTINEOPLASTIC AGENTS; ARTERIAL OCCLUSIVE DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG TOXICITY; FEAR; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PULMONARY ARTERY; RISK ASSESSMENT;

EID: 84862338618     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.03.010     Document Type: Editorial

References (14)

1. Selvin E., Erlinger T.P. Prevalence and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004, 110(6):738-743.
2. Aichberger K.J., Herndlhofer S., Schernthaner G.H., Schillinger M., Mitterbauer-Hohendanner G., Sillaber C., et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011, 86(7):533-539.
3. Le Coutre P., Rea D., Abruzzese E., Dombret H., Trawinska M.M., Herndhofer S., et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011, 103(17):1347-1348.
4. Hadzijusufovic E., Herndlhofer S., Aichberger K.J., Ghanim V., Suppan V., Cerny-Reiterer S., et al. Nilotinib exerts direct effects on vascular endothelial cells and may act as a co-trigger of atherosclerosis in patients with Ph+ CML. Blood 2011, 118. abstr 2753.
5. Giles F., Mauro M.J., Hong F., Ortmann C.E., Woodman R.C., Le Coutre P., et al. Retrospective cohort analysis of peripheral arterial occlusive disease (PAOD) events in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood 2011, 118. Abstract 2757.
6. Agarwal R., Gomberg-Matland M. Current therapeutics and practical management strategies for pulmonary arterial hypertension. Am Heart J 2011, 162(2):201-213.
7. EMEA: Sprycel-Scientific discussion. European Public Assessment Report (EPAR 2011).
8. Quintas-Cardama A., Kantarjian H., O'Brien S., Borthakur G., Bruzzi J., Munden R., et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007, 25(25):3908-3914.
9. Rasheed W., Flaim B., Seymour J.F. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009, 33(6):861-864.
10. Mattei D., Feola M., Orzan F., Mordini N., Rapezzi D., Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009, 43(12):967-968.
11. Dumitrescu D., Seck C., Ten Freyhaus H., Gerhardt F., Erdmann E., Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Eur Respir J 2011, 38(1):218-220.
12. Hennigs J.K., Keller G., Baumann H.J., Honecker F., Kluge S., Bokemeyer C., et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?. BMC Pulm Med 2011, 23:11-30.
13. Orlandi E.M., Rocca B., Pazzano A.S., Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low dose dasatinib treatment for chronic myeloid leukemia. Leuk Res 2012, 36(81):e4-e6.
14. Kantarjian H.M., Shah N.P., Cortes J.E., Baccarani M., Agarwal M.B., Undurraga M.S., et al. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012, 119:1123-1129.